Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOR46 and Enzalutamide in Metastatic Castration Resistant Prostate Cancer
NCT05011188Phase 2Active, not recruiting
- Sponsor
- Rahul Aggarwal
- Start
- Jan 2022
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Rahul Aggarwal. Primary endpoints: Maximally Tolerated Dose at 3 weeks, Dose-Limiting Toxicities at 3 weeks and 1 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
FG-3246
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05011188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011188.